Evidence map›Paper›PMID 32168910›Full record

ArticleCancers2020

MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells.

Athena F Phoa, Ariadna Recasens, Fadi M S Gurgis, Tara A Betts, Sharleen V Menezes, Diep Chau, Kristiina Nordfors, Joonas Haapasalo, Hannu Haapasalo, Terrance G Johns and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Frontiers in neurology · 2024
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Athena F PhoaSchool of Medical Sciences, Charles Perkins Centre and Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia.
Ariadna RecasensSchool of Medical Sciences, Charles Perkins Centre and Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia.
Fadi M S GurgisSchool of Medical Sciences, Charles Perkins Centre and Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia.
Tara A BettsSchool of Medical Sciences, Charles Perkins Centre and Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia.
Sharleen V MenezesSchool of Medical Sciences, Charles Perkins Centre and Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia.
Diep ChauInflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Kristiina NordforsDepartment of Pediatrics, Tampere University Hospital, 33521 Tampere, Finland.
Joonas HaapasaloThe Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.
Hannu HaapasaloDepartment of Pathology, Fimlab Laboratories, Tampere University Hospital, FI-33521 Tampere, Finland.
Terrance G JohnsOncogenic Signalling Laboratory, Telethon Kids Institute, Perth Children's Hospital, 15 Hospital Avenue, Nedlands, WA 6009, Australia.
Brett W StringerQIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia.
Bryan W DayQIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia.
Michael E BucklandSchool of Medical Sciences, Charles Perkins Centre and Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia.
Najoua LalaouiInflammation Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Lenka MunozSchool of Medical Sciences, Charles Perkins Centre and Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia.
The University of Sydney · AUQIMR Berghofer Medical Research Institute · AUThe University of Melbourne · AUHospital for Sick Children · CATampere University · FITampere University Hospital · FIThe Kids Research Institute Australia · AU

Funding

National Health and Medical Research Council APP1163484
6 · The paper itself

Abstract

MAPK-activated protein kinase 2 (MK2) has diverse roles in cancer. In response to chemotherapy, MK2 inhibition is synthetically lethal to p53-deficiency. While

Indexed as

glioblastomaMK2p53senescencetemozolomide

Identifiers

PMID32168910
PMCPMC7139970
OpenAlexW3010816477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.